NEW YORK, Nov. 4, 2016 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Impax Laboratories Inc. (NASDAQ: IPXL) resulting from allegations that Impax may have issued materially misleading business information to the investing public.

According to news reports, United States prosecutors may file criminal charges against Impax by the end of 2016 for suspected price collusion.

On November 3, 2016, Bloomberg reported that the "antitrust investigation by the Justice Department, begun about two years ago, now spans more than a dozen companies and about two dozen drugs, according to people familiar with the matter. The grand jury probe is examining whether some executives agreed with one another to raise prices, and the first charges could emerge by the end of the year, they said." On this news, Impax fell sharply, damaging investors.